Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms
- PMID: 31121491
- PMCID: PMC6529825
- DOI: 10.1016/j.tranon.2019.04.020
Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms
Abstract
Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients' tumor and immune system, and predict patients' responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Humanized mouse model: a review on preclinical applications for cancer immunotherapy.Am J Cancer Res. 2020 Dec 1;10(12):4568-4584. eCollection 2020. Am J Cancer Res. 2020. PMID: 33415020 Free PMC article. Review.
-
Mouse Models for Cancer Immunotherapy Research.Cancer Discov. 2018 Nov;8(11):1358-1365. doi: 10.1158/2159-8290.CD-18-0044. Epub 2018 Oct 11. Cancer Discov. 2018. PMID: 30309862 Free PMC article. Review.
-
Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.Cancers (Basel). 2023 May 30;15(11):2989. doi: 10.3390/cancers15112989. Cancers (Basel). 2023. PMID: 37296949 Free PMC article. Review.
-
Humanized Rodent Models for Cancer Research.Front Oncol. 2020 Sep 11;10:1696. doi: 10.3389/fonc.2020.01696. eCollection 2020. Front Oncol. 2020. PMID: 33042811 Free PMC article. Review.
-
Immunotherapies and Metastatic Cancers: Understanding Utility and Predictivity of Human Immune Cell Engrafted Mice in Preclinical Drug Development.Cancers (Basel). 2020 Jun 18;12(6):1615. doi: 10.3390/cancers12061615. Cancers (Basel). 2020. PMID: 32570871 Free PMC article. Review.
Cited by
-
Animal Models of Hepatocellular Carcinoma for Local-Regional Intraarterial Therapies.Radiol Imaging Cancer. 2022 Jul;4(4):e210098. doi: 10.1148/rycan.210098. Radiol Imaging Cancer. 2022. PMID: 35838531 Free PMC article. Review.
-
Recent Developments in NSG and NRG Humanized Mouse Models for Their Use in Viral and Immune Research.Viruses. 2023 Feb 9;15(2):478. doi: 10.3390/v15020478. Viruses. 2023. PMID: 36851692 Free PMC article. Review.
-
TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth.Commun Biol. 2022 Jan 12;5(1):42. doi: 10.1038/s42003-021-02958-6. Commun Biol. 2022. PMID: 35022561 Free PMC article.
-
Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line.Cancer Biol Ther. 2020 Jun 2;21(6):495-502. doi: 10.1080/15384047.2020.1738907. Epub 2020 Mar 25. Cancer Biol Ther. 2020. PMID: 32208894 Free PMC article. Review.
-
Patient-Derived Xenograft Models in Urological Malignancies: Urothelial Cell Carcinoma and Renal Cell Carcinoma.Cancers (Basel). 2020 Feb 13;12(2):439. doi: 10.3390/cancers12020439. Cancers (Basel). 2020. PMID: 32069881 Free PMC article. Review.
References
-
- Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17:286–301. - PubMed
-
- Del Paggio JC. Immunotherapy: Cancer immunotherapy and the value of cure. Nat Rev Clin Oncol. 2018;15:268–270. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous